Arcus Biosciences (RCUS) to Release Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $29.4850 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.22. The business had revenue of $33.00 million for the quarter, compared to analyst estimates of $24.94 million. Arcus Biosciences had a negative return on equity of 65.77% and a negative net margin of 142.91%.The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.03) earnings per share. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arcus Biosciences Price Performance

Shares of RCUS stock opened at $25.72 on Monday. The stock has a 50-day moving average price of $22.55 and a 200 day moving average price of $21.91. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.16. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -7.80 and a beta of 0.87. Arcus Biosciences has a 12 month low of $7.06 and a 12 month high of $28.72.

Institutional Trading of Arcus Biosciences

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its holdings in Arcus Biosciences by 253.9% during the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock valued at $714,000 after purchasing an additional 65,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Arcus Biosciences by 10.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after purchasing an additional 3,565 shares during the period. Millennium Management LLC raised its holdings in Arcus Biosciences by 29.2% in the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after purchasing an additional 270,253 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Arcus Biosciences by 106.2% during the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after purchasing an additional 470,755 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Arcus Biosciences in the 1st quarter valued at $67,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RCUS has been the topic of several recent research reports. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the company an “equal weight” rating in a research note on Thursday, February 12th. Citigroup increased their price objective on shares of Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Arcus Biosciences in a research note on Monday, March 2nd. Wall Street Zen raised shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average target price of $32.44.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.